Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 10/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23388810 | 1.00 | RXFP1 (0.42) | RXFP1ABCG2MAPK8AURKAAURKB | |
| SCHEMBL22571385 | 0.94 | RXFP1 (0.43) | RXFP1ABCG2MAPK8AURKAAURKB | |
| SCHEMBL23423242 | 0.87 | LMNA (0.45) | MEN1KMT2APTGS1 | |
| SCHEMBL23388931 | 0.83 | MAPK8 (0.38) | RXFP1ABCG2MAPK8AURKAAURKB | |
| SCHEMBL23423434 | 0.81 | LMNA (0.46) | MEN1KMT2APTGS1 | |
| SCHEMBL30323324 | 0.81 | TLR7 (0.43) | RXFP1AURKAAURKB | |
| SCHEMBL30323356 | 0.81 | TLR7 (0.43) | RXFP1AURKAAURKB | |
| SCHEMBL22556300 | 0.79 | RXFP1 (0.49) | RXFP1ABCG2MAPK8TAS2R14AKR1C3 | |
| SCHEMBL22556551 | 0.79 | RXFP1 (0.46) | RXFP1ABCG2MAPK8TAS2R14AKR1C3 | |
| SCHEMBL22556353 | 0.78 | RXFP1 (0.44) | RXFP1ABCG2MAPK8TAS2R14AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279368-B | Heteroaryl compounds | 维瓦斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-115279368-A | Heteroaryl compounds | 维瓦斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4061364-A1 | HETEROARYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |